Jan J Cornelissen
Overview
Explore the profile of Jan J Cornelissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
7712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaplan Z, van Leeuwen N, van Klaveren D, Visser O, Posthuma E, van Lammeren-Venema D, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000264.
PMID: 39886140
Objective: Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may differ among healthcare professionals. This nationwide, population-based study...
2.
Yousefi A, Levin M, Cornelissen J, Westerweel P
Ann Hematol
. 2025 Jan;
PMID: 39792178
Selected chronic myeloid leukemia (CML) patients may discontinue their tyrosine kinase inihibitor (TKI) in an attempt to achieve sustained treatment-free remission (TFR), which mitigates therapy-related side effects and limits treatment...
3.
Broers A, Meijer E, van der Holt B, de Jong C, Nur E, van Sluis G, et al.
Hemasphere
. 2024 Dec;
8(12):e70040.
PMID: 39665067
Cyclosporine A combined with mycophenolate mofetil (CsA/MMF) has become an established regimen for the prevention of graft-versus-host disease (GVHD) following non-myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (alloHSCT). However, the...
4.
Kockerols C, Valk P, Hogenbirk P, Cornelissen J, Westerweel P
J Mol Diagn
. 2024 Nov;
27(2):109-118.
PMID: 39615652
BCR::ABL1 digital PCR is a promising technique for the quantification of deep molecular responses (DMRs) in chronic myeloid leukemia. It provides an improved precision and sensitivity compared with conventional real-time...
5.
Hermans S, van der Maas N, van Norden Y, Dinmohamed A, Berkx E, Huijgens P, et al.
JAMA Oncol
. 2024 Aug;
10(10):1426-1436.
PMID: 39207765
Importance: The use of real-world data (RWD) external control arms in prospective studies is increasing. The advantages, including the immediate availability of a control population, must be balanced with the...
6.
Mohty R, Bazarbachi A, Labopin M, Esteve J, Kroger N, Cornelissen J, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1534-1541.
PMID: 39143183
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations have uncertain prognostic implications in AML. We investigate the impact IDH1 and IDH2 mutations in AML patients undergoing allogeneic hematopoietic cell...
7.
Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U, et al.
Transplant Cell Ther
. 2024 Jul;
31(1):14.e1-14.e10.
PMID: 39069077
The use of tyrosine kinase inhibitors (TKIs) during induction and consolidation, followed by allogeneic hematopoietic cell transplantation (allo-HCT), is a standard of care for patients with Philadelphia (Ph)-positive acute lymphoblastic...
8.
Kockerols C, Valk P, Janssen J, Hogenbirk P, Cornelissen J, Saussele S, et al.
Eur J Haematol
. 2024 Jul;
113(5):606-613.
PMID: 38994654
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth...
9.
Kockerols C, Valk P, Dulucq S, Nicolini F, Mahon F, Atallah E, et al.
Am J Hematol
. 2024 May;
99(8):1632-1635.
PMID: 38769689
No abstract available.
10.
Scheid C, Eikema D, van Gelder M, Salmenniemi U, Maertens J, Passweg J, et al.
Blood
. 2024 May;
144(4):445-456.
PMID: 38728380
In patients with myelodysplastic syndrome (MDS), higher revised International Prognostic Scoring System (IPSS-R) scores at transplant are associated with worse transplant outcome and, thus, lowering IPSS-R scores by therapeutic intervention...